Labuxtinib

CAS No. 1426449-01-5

Labuxtinib( —— )

Catalog No. M37250 CAS No. 1426449-01-5

Labutinib is a selective inhibitor of the c-kit tyrosine kinase .

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 373 In Stock
5MG 337 In Stock
10MG 541 In Stock
25MG 1074 In Stock
50MG 1516 In Stock
100MG 2037 In Stock
200MG 2744 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Labuxtinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Labutinib is a selective inhibitor of the c-kit tyrosine kinase .
  • Description
    Labuxtinib is c-kit tyrosine kinase inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR | c-Kit
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1426449-01-5
  • Formula Weight
    377.37
  • Molecular Formula
    C20H16FN5O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 125 mg/mL (331.24 mM; Ultrasonic )
  • SMILES
    C(NC1=CC(=CC=C1C)C=2N=C(ON2)[C@@H]3[C@@H](F)C3)(=O)C=4N5C(=NC4)C=CC=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Yeh Vince, et al. Imidazopyridine compounds and compositions as c-kit kinase inhibitors and their preparation. World Intellectual Property Organization, WO2013033070 A1. 2013-03-07.
molnova catalog
related products
  • AG-1517

    PD153035 hydrochloride is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.

  • UNC0631

    UNC0631 is a effectvie histone methyltransferase G9a inhibitor (IC50=4 nM).

  • AZD-9291 dimesylate

    A potent, selective, third-generation irreversible inhibitor of mutant EGFR with IC50s of 1/12/5 nM for L858R-T790M/L858R/L861Q respectively.